Stockholm, 2015-06-09 08:30 CEST (GLOBE NEWSWIRE) --
Rosemary Cunningham Thomas has broad experience leading companies through critical growth stages to become industry-leading players with good profitability. She has been the CEO of UK-based ToHealth Ltd., interim CEO of FreeHand 2010 Ltd. and European President & General Manager of Galil Medical. Prior to that, she was Sales and Marketing Director for CR Bard, Inc., listed on the New York Stock Exchange. Rosemary has also held several key positions at Smiths Industries Med Systems (now Smiths Medical) listed on the FTSE 100, as Speciality Business Unit Manager, Sales and Marketing Director and Clinical Development Specialist responsible for commercial partnerships. Rosemary has an educational background in pharmacy and economics.
"We are delighted to welcome Rosemary Cunningham Thomas as the new CEO of Episurf Medical. The company is in a growth phase with a strong focus on sales and marketing in Europe and eventually North America. Rosemary's experience in leading organizations to profitability and generating growth in international markets will be valuable to Episurfs continued development", comments Saeid Esmaeilzadeh, Chairman of Episurf Medical AB.
"Episurf Medical has a very interesting platform technology addressing a growing global market. What attracted me is the company's innovative technology, broad patent portfolio and unique know how in personalized treatments for people with joint problems. I’m very glad to be joining Episurf and believe that my experience has well equipped me to lead the company towards becoming an industry leader and a pioneer in the field of patient specific orthopedic treatments’’, says Rosemary Cunningham Thomas.
For more information, please contact:
Saeid Esmaeilzadeh, Chairman of Episurf Medical AB
Tel: +46-707187061
E-post: ir@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
